Literature DB >> 22899222

Diagnostic values of GHSR DNA methylation pattern in breast cancer.

Sandeep Kumar Botla1, Amin Moghaddas Gholami, Mahdi Malekpour, Evgeny A Moskalev, Mahdi Fallah, Pouria Jandaghi, Ali Aghajani, Irina S Bondar, Ramesh Omranipour, Fatemeh Malekpour, Abbas Mohajeri, Azin Jahangiri Babadi, Özgür Sahin, Vladimir V Bubnov, Hossein Najmabadi, Jörg D Hoheisel, Yasser Riazalhosseini.   

Abstract

DNA methylation patterns have been recognised as cancer-specific markers with high potential for clinical applications. We aimed at identifying methylation variations that differentiate between breast cancers and other breast tissue entities to establish a signature for diagnosis. Candidate genomic loci were analysed in 117 fresh-frozen breast specimens, which included cancer, benign and normal breast tissues from patients as well as material from healthy individuals. A cancer-specific DNA methylation signature was identified by microarray analysis in a test set of samples (n = 52, p < 2.1 × 10(-4)) and its performance was assessed through bisulphite pyrosequencing in an independent validation set (n = 65, p < 1.9 × 10(-7)). The signature is associated with SFRP2 and GHSR genes, and exhibited significant hypermethylation in cancers. Normal-appearing breast tissues from cancer patients were also methylated at these loci but to a markedly lower extent. This occurrence of methylated DNA in normal breast tissue of cancer patients is indicative of an epigenetic field defect. Concerning diagnosis, receiver operating characteristic curves and the corresponding area under the curve (AUC) analysis demonstrated a very high sensitivity and specificity of 89.3 and 100 %, respectively, for the GHSR methylation pattern (AUC >0.99). To date, this represents the DNA methylation marker of the highest sensitivity and specificity for breast cancer diagnosis. Functionally, ectopic expression of GHSR in a cell line model reduced breast cancer cell invasion without affecting cell viability upon stimulation of cells with ghrelin. Our data suggest a link between epigenetic down-regulation of GHSR and breast cancer cell invasion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22899222     DOI: 10.1007/s10549-012-2197-z

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  GHSR hypermethylation: a promising pan-cancer marker.

Authors:  Pouria Jandaghi; Jörg D Hoheisel; Yasser Riazalhosseini
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Validation of DNA promoter hypermethylation biomarkers in breast cancer--a short report.

Authors:  Jolien S de Groot; Xiaojuan Pan; Jan Meeldijk; Elsken van der Wall; Paul J van Diest; Cathy B Moelans
Journal:  Cell Oncol (Dordr)       Date:  2014-08-16       Impact factor: 6.730

3.  Low expression of secreted frizzled-related protein 4 in aggressive pituitary adenoma.

Authors:  Youtu Wu; Jiwei Bai; Zhenye Li; Fei Wang; Lei Cao; Chunhui Liu; Shengyuan Yu; Guoqiang Yu; Yazhuo Zhang
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

4.  Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer.

Authors:  Ridho Assidicky; Unal Metin Tokat; Ibrahim Oguzhan Tarman; Ozge Saatci; Pelin Gulizar Ersan; Umar Raza; Hasan Ogul; Yasser Riazalhosseini; Tolga Can; Ozgur Sahin
Journal:  Breast Cancer Res Treat       Date:  2022-03-25       Impact factor: 4.624

5.  GHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers.

Authors:  Evgeny A Moskalev; Pouria Jandaghi; Mahdi Fallah; Mehdi Manoochehri; Sandeep K Botla; Oleg V Kolychev; Evgeny A Nikitin; Vladymyr V Bubnov; M von Knebel Doeberitz; Oliver Strobel; Thilo Hackert; Markus W Büchler; Nathalia Giese; Andrea Bauer; Thomas Muley; Arne Warth; Peter Schirmacher; Florian Haller; Jörg D Hoheisel; Yasser Riazalhosseini
Journal:  Oncotarget       Date:  2015-02-28

6.  Protein Profiling Gastric Cancer and Neighboring Control Tissues Using High-Content Antibody Microarrays.

Authors:  Martin Sill; Christoph Schröder; Ying Shen; Aseel Marzoq; Radovan Komel; Jörg D Hoheisel; Henrik Nienhüser; Thomas Schmidt; Damjana Kastelic
Journal:  Microarrays (Basel)       Date:  2016-07-08

7.  Neuropeptide receptor genes GHSR and NMUR1 are candidate epigenetic biomarkers and predictors for surgically treated patients with oropharyngeal cancer.

Authors:  Kiyoshi Misawa; Masato Mima; Yamada Satoshi; Yuki Misawa; Atsushi Imai; Daiki Mochizuki; Takuya Nakagawa; Tomoya Kurokawa; Miki Oguro; Ryuji Ishikawa; Yuki Yamaguchi; Shiori Endo; Hideya Kawasaki; Takeharu Kanazawa; Hiroyuki Mineta
Journal:  Sci Rep       Date:  2020-01-23       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.